Afatinib News and Research

RSS
Penn studies provide new understanding of lung cancer progression and prevention

Penn studies provide new understanding of lung cancer progression and prevention

Gene expression patterns could help predict treatment for breast cancer, research shows

Gene expression patterns could help predict treatment for breast cancer, research shows

Added benefit of lung cancer drug not proven, says IQWiG

Added benefit of lung cancer drug not proven, says IQWiG

Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Post-progression afatinib exposure boosts NSCLC outcomes

Post-progression afatinib exposure boosts NSCLC outcomes

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

LUX-Lung 8 supports afatinib in squamous NSCLC

LUX-Lung 8 supports afatinib in squamous NSCLC

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Researchers identify multiple types of resistance to new targeted lung cancer drug

Researchers identify multiple types of resistance to new targeted lung cancer drug

New drug shows promise against treatment-resistant non-small cell lung cancer

New drug shows promise against treatment-resistant non-small cell lung cancer

Afatinib active against NSCLC nervous system metastases

Afatinib active against NSCLC nervous system metastases

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer